Aptimmune Selected for Yield Lab Accelerator

Categories : EnterpriseWorks, Recognition & Awards
Posted on: November 17, 2016

CHAMPAIGN — Aptimmune Biologics was selected by The Yield Lab, a St. Louis-based agriculture technology business accelerator and investor, to participate in a nine-month program designed to support emerging ag tech companies. Aptimmune Biologics was chosen from among 120 applicants to participate in the program for 2016 and represents The Yield Labs first animal health investment.

Aptimmune Biologics, based in Champaign, Illinois, is developing and will soon launch innovative autogenous mucosal vaccines to help producers prevent major swine viral diseases. “We are honored that The Yield Lab has chosen to invest in Aptimmune and to share its business accelerator expertise with us,” says Aaron Gilbertie, CEO of Aptimmune Biologics. “We are among a very select group of emerging ag technology companies that The Yield Lab has selected to invest in and we believe their support and business resources will help us bring new, highly-effective animal health products to market more quickly.”

“Aptimmune is a company with extensive technical expertise, and the vaccine products they are developing have the potential to greatly improve swine health and food production in general,” says Matt Plummer, Principal at The Yield Lab. “The entire Aptimmune team has been tremendous to work with, and we believe the company is deriving value from The Yield Lab business accelerator program.”

Based in St. Louis, Mo., The Yield Lab is the nation’s first and largest agriculture technology business accelerator, maintaining its investment focus entirely on early-stage development of ag tech companies that offer creative and innovative solutions to the food and agriculture industry. The Yield Lab provides mentorship, networking and funding to hand-selected companies during a nine-month period.

Aptimmune Biologics, based in Champaign, Ill., specializes in developing and marketing a portfolio of revolutionary mucosal vaccines that provide answers for the most costly viral diseases impacting the swine industry. Aptimmune’s first vaccines are focused on addressing two major viral respiratory pathogens, Porcine Reproductive and Respiratory Virus (PRRSV) and influenza.